Keros Therapeutics (KROS) Preferred Stock Liabilities (2019 - 2020)
Keros Therapeutics (KROS) reported Preferred Stock Liabilities of $55.8 million for Q1 2020, up 512.57% on a YoY basis from $9.1 million in Q2 2019, and up 179.73% quarter-over-quarter from $19.9 million in Q4 2019.
Keros Therapeutics (KROS) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends
Keros Therapeutics has reported Preferred Stock Liabilities for 2 years, with the latest figure at $55.8 million in Q1 2020.
- For the quarter ending Q1 2020, Preferred Stock Liabilities rose 512.57% year-over-year to $55.8 million; the trailing twelve-month figure through Mar 2020 stood at $55.8 million (up 512.57% YoY), and the FY2019 full-year result was $19.9 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q1 2020 stood at $55.8 million, up from $19.9 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $55.8 million in Q1 2020, with the low at $9.1 million in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Keros Therapeutics | 399.01 Mn | 111.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 55.78 Mn |
| Dec 31, 2019 | 19.94 Mn |
| Sep 30, 2019 | 9.89 Mn |
| Jun 30, 2019 | 9.11 Mn |
| Mar 31, 2019 | 9.11 Mn |